Poster Session 1
AB030. PS01.12. A phase II study of regorafenib in patients with thymoma and thymic carcinoma previously treated with chemotherapy
Mediastinum
2017;
1:
AB030
(12 September 2017)
Poster Session 1
AB029. PS01.11. Thymomas are the potential candidates for the immune checkpoint inhibitors therapy
Mediastinum
2017;
1:
AB029
(12 September 2017)
Poster Session 1
AB028. PS01.10. Iodine-125 SEED implantation for thymic tumor pleural relapse after failure of chemoradiotherapy
Mediastinum
2017;
1:
AB028
(12 September 2017)
Poster Session 1
AB027. PS01.09. In-progress: phase 1b study of anetumab ravtansine in patients with mesothelin-expressing malignancies
Mediastinum
2017;
1:
AB027
(12 September 2017)
Poster Session 1
AB026. PS01.08. Acetylcholine receptor antibody levels correlate with clinical status in myasthenic thymomas and non-thymomas
Mediastinum
2017;
1:
AB026
(12 September 2017)
Poster Session 1
AB025. PS01.07. Appropriate time to adjuvant radiotherapy for thymoma with myasthenia gravis after extended thymectomy
Mediastinum
2017;
1:
AB025
(12 September 2017)
Poster Session 1
AB024. PS01.06. Exploring the genomic heterogeneity of the combined B2-B3 thymoma and nodal metastasis
Mediastinum
2017;
1:
AB024
(12 September 2017)
Poster Session 1
AB023. PS01.05. Clinical outcomes for stage-III thymic squamous carcinoma
Mediastinum
2017;
1:
AB023
(12 September 2017)
Poster Session 1
AB022. PS01.04. Myasthenia gravis in thymic epithelial tumors incidence and prognosis
Mediastinum
2017;
1:
AB022
(12 September 2017)
Poster Session 1
AB021. PS01.03. Copy number alteration and gene expression analysis of surgically resected thymic epithelial tumors
Mediastinum
2017;
1:
AB021
(12 September 2017)
Poster Session 1
AB020. PS01.02. Identification of potential biomarkers in thymectomy specimen from myasthenia gravis patients in the MGTX-trial
Mediastinum
2017;
1:
AB020
(12 September 2017)
Poster Session 1
AB019. PS01.01. Diagnostic and prognostic implications of fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in thymic epithelial tumors
Mediastinum
2017;
1:
AB019
(12 September 2017)
Surgery
AB018. OS04.04. Is video-assisted thymectomy appropriate for large thymomas? Results of a propensity score matching analysis
Mediastinum
2017;
1:
AB018
(12 September 2017)
Surgery
AB017. OS04.03. Impact of lymph node dissection for thymic malignancies: multi-institutional propensity score matched analysis
Mediastinum
2017;
1:
AB017
(12 September 2017)
Surgery
AB016. OS04.02. Comparision of left and right-sided approach video-assisted thymectomy for centrally located thymic tumors
Mediastinum
2017;
1:
AB016
(12 September 2017)
Surgery
AB015. OS04.01. Robotic thymectomy in thymic epithelial tumors: a propensity score matching study of 112 consecutive cases
Mediastinum
2017;
1:
AB015
(11 September 2017)
Translational Science
AB014. OS03.04. Thymic epithelial tumors phenotype relies on MIR-145-5p epigenetic regulation
Mediastinum
2017;
1:
AB014
(12 September 2017)
Translational Science
AB013. OS03.03. Quantitative proteomic analysis of type B thymoma using data independent acquisition mass spectrometry
Mediastinum
2017;
1:
AB013
(12 September 2017)
Translational Science
AB012. OS03.02. Paraneoplastic syndrome and survival in thymic epithelial tumors the IU experience
Mediastinum
2017;
1:
AB012
(12 September 2017)
Translational Science
AB011. OS03.01. Expression of L-type amino acid transporter 1 is possible diagnostic and prognostic marker of thymic carcinoma
Mediastinum
2017;
1:
AB011
(12 September 2017)
Basic Science
AB010. OS02.04. Characterization of autoantibody in thymoma with myasthenia gravis by single-cell sequencing of B-cells
Mediastinum
2017;
1:
AB010
(12 September 2017)
Basic Science
AB009. OS02.03. Phase II trial of cetuximab and chemotherapy followed by surgical resection for locally advanced thymoma
Mediastinum
2017;
1:
AB009
(12 September 2017)
Editorial
Robotic approach for mediastinal lesions: the surgery of extreme locations
Mediastinum
2017;
1:
8
(30 September 2017)
Basic Science
AB008. OS02.02. Identification of differentially expressed genes between thymoma and paraneoplastic thymic tissues
Mediastinum
2017;
1:
AB008
(12 September 2017)
Editorial
Thymic epithelial tumors: still enigmatic neoplasms!
Mediastinum
2017;
1:
7
(30 September 2017)
Basic Science
AB007. OS02.01. The integrated genomic landscape of thymic epithelial tumors: a report by the TCGA research network
Mediastinum
2017;
1:
AB007
(12 September 2017)
Editorial
Setting the base for new therapeutic strategies against thymic epithelial tumors—miR-145-5p epigenetic regulation
Mediastinum
2017;
1:
6
(30 September 2017)
Clinical Science
AB006. OS01.06. Factors associated with survival in patients with thymoma: study of 523 cases from one institution
Mediastinum
2017;
1:
AB006
(12 September 2017)
Clinical Science
AB005. OS01.05. Early prediction of response to target therapy by FDG-PET in thymic epithelial tumors: a monocentric experience
Mediastinum
2017;
1:
AB005
(12 September 2017)
Clinical Science
AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC
Mediastinum
2017;
1:
AB004
(12 September 2017)
Editorial
Relevance of PD-L1 expression status in thymic malignancies
Mediastinum
2017;
1:
3
(15 September 2017)
Clinical Science
AB003. OS01.03. New proposed treatment for pure red cell aplasia thymoma-related
Mediastinum
2017;
1:
AB003
(12 September 2017)
Clinical Science
AB002. OS01.02. A phase ii study of chemotherapy concurrent with radiotherapy in patients with unresectable advanced thymic tumors
Mediastinum
2017;
1:
AB002
(12 September 2017)
Clinical Science
AB001. OS01.01. Post op radiation may be detrimental in thymoma but not in thymic carcinoma tumors
Mediastinum
2017;
1:
AB001
(12 September 2017)
Editorial
Old wine in new bottles: C-reactive protein (CRP) is a promising tumor marker in thymic epithelial tumors
Mediastinum
2017;
1:
2
(31 August 2017)